ArriVent BioPharma, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD from Q4 2022 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
-
Summary
-
ArriVent BioPharma, Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and growth rate from Q4 2022 to Q3 2024.
- ArriVent BioPharma, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending September 30, 2024 was $283M, a 100% increase year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Growth (%)